As interest in taking glucagon-like peptide-1 receptor agonist (GLP-1 agonist) medications, such as Zepbound and Wegovy, for weight loss, research continues to examine potential new side effects of these types of drugs
Yes, semaglutide is a GLP-1 receptor agonist, and Ozempic is one of the brand names
One regulatory note worth holding alongside his framing: the FDA placed several of the peptides he discusses (including BPC-157, CJC-1295, and Ipamorelin) onto a Category 2 list in 2023, citing a lack of safety data rather than reported harms
It is unknown if patients with a history of pancreatitis are at higher risk for development of pancreatitis on WEGOVY
That said, visual and physical signs of degradation do occur, and when they appear, they indicate advanced degradation that demands immediate action